專任教授(生物醫學組)-中央大學生命科學系資訊網

• 現  職：

國立中央大學 生命科學系   副教授    (2024~present)

• 學  歷：

國立陽明交通大學  生物醫學影像暨放射科學系 博士 (2011~2014)

國立陽明交通大學  生物醫學影像暨放射科學系 碩士 (2010~2011)

中國醫藥大學   生物醫學影像暨放射科學系   學士 (2006~2010)

• 經  歷：

國立中央大學 生命科學系   副教授    (2024~present)

美國紐約大學 朗格尼醫學中心  訪問學者 (2024.07-09/2025.07-09)

中國醫藥大學生物科技學系 副教授 (2021.08~2024.01)

澳洲墨爾本大學 眼科研究中心  訪問學者 (2021.07-09)

中國醫藥大學  生物科技學系 助理教授 (2018~2021)

臺北醫學大學  醫學系 放射線學科 助理教授 (2017~2018)

臺北醫學大學附設醫院  博士後研究員 (2014~2017)

美國加州爾灣大學 交流學生 (2008 .07-09)

(請參考實驗室網頁https://1440114.wixsite.com/sakiro920)

Our group is mainly working on therapeutic evaluation of tumor oncology with various molecular image system support. 1) We had successfully established various molecular image monitoring systems on more than 8 types of cancer models, including glioblastoma, non-small cell lung cancer, hepatocellular carcinoma, bladder cancer, colon cancer, osteosarcoma…etc. 2) For oncology therapies development, we try to identify possible combination treatment strategies, possible Chinese herb and also drug repurposing evaluation. 3) Importantly, we constructed suitable mesenchymal stem cells tracking image system by MRI. This may effectively support cell-based therapy to dynamically identify delivery and treatment efficacy. Cell-based therapy system, is a “Living Drugs” system, which display better potential to fight cancer. Fabricate MSCs based gene delivery system may be used as a promising anti-tumor agent, which could provide a new benefit for cancer patients. 4) Furthermore, we are also trying to establish theranostic probe platform in oncology field by combination of target therapy drug, microRNA expression and MRI, which will be helpful in comprehensive understanding and management of cancer. 5) Immune based antibody therapy is another project of our group. We try to investigate various combination strategy of antibodies combination therapy on melanoma, colon rectal carcinoma and glioblastoma. Several patents was also preparing according to our latest finding. Our researches are focus on comprehensively encompass molecular images and therapeutic strategies to improve the cancer management. Thus, the major GOAL of our research is the provision of new insights into oncology therapeutic approaches and aimed at prolonging the overall patient survival.

•New therapeutic compounds

      --small molecular drugs, Chinese herb

•Immunotherapies

      --antibodies combination therapy

      --low dose chemo combined immune cells therapies

•Theranostic probes design and application

      --fluorescence+drug, shRNA, antibody (molecular image)

      --Immune regulation nanoparticles

•Cells based therapies on drug resistance model

      --T cell therapy, stem cells therapy, cancer stem cells

      --Gene modified WJ-MSCs cell therapy

•Molecular images on cancer

      --Specific gene alteration (Bioluminescence imaging)

國際期刊(Google Scholar:https://scholar.google.com.tw/citations?user=Obwro0gAAAAJ&hl=zh-TW&oi=ao)

重要發表 (其餘發表請參考實驗室網頁https://1440114.wixsite.com/sakiro920)

1. Hsu FT*,#, Chen YZ*, Chin YC*, Chang LC*, Chiang SC, Yang LX, Liu HS, Yueh PF, Tu HL, He RU, Jeng LB, Shyu WC, Hu SH, Chiang IT, Liu YC, Chiu YC, Wu C, Yu CC, Su WP#, Huang CC# (2024) :  Harnessing the Power of Sugar-Based Nanoparticles: A Drug-Free Approach to Enhance Immune Checkpoint Inhibition against Glioblastoma and Pancreatic Cancer. ACS Nano doi: 10.1021/acsnano.4c07903. 
2. Yueh PF, Chiang CS, Tsai IJ, Yseng YL, Chen HR, Lan KL*, Hsu FT* (2024): A Multifunctional PEGylated Liposomal-Encapsulated Sunitinib Enhancing Autophagy, Immunomodulation, and Safety in Renal Cell Carcinoma. Journal of Nanobiotechnology 22(1):459. doi: 10.1186/s12951-024-02664-5.
3. Cheng HW, Lee W, Hsu FT, Lai YH, Huang SR, Lim SH, Lin ZK, Hsu SC, Chiang CS, Jeng LB, Shyu WC, Chen SY (2024): Manipulating the Crosstalk between Cancer and Immunosuppressive Cells with Phototherapeutic Gold-Nanohut for Reprogramming Tumor Microenvironment. Advanced Science 2024, 11, 2404347 doi: 10.1002/advs.202404347
4. Peng PH, Chen JL, Wu HH, Yang WH, Lin LJ, Lai CY, Chang JS, Syu JL, Wu HT, Hsu FT*, Cheng WC* and Hsu KW* (2023): Interplay between lncRNA RP11-367G18.1 variant 2 and YY1 plays a vital role in hypoxia-mediated gene expression and tumorigenesis. Cancer Cell International 23(1):266. doi: 10.1186/s12935-023-03067-6
5. Hsu FT, Liu WL, Lee SR, Jeng LB, Chen JH (2023): Unveiling nature’s potential weapon: Magnolol’s role in combating bladder cancer by upregulating the miR-124 and inactivating PKC-δ/ERK axis. Phytomedicine 119, 154947. doi: 10.1016/j.phymed.2023.154947
6. Yang CJ, Tan ZL, Yang JD, Hsu FT, Chiang CH (2023): Fluoxetine inactives STAT3/NF-κB signaling and promotes the sensitivity to cisplain in bladder cancer. Biomedicine & Pharmacotherapy 164:114962. doi: 10.1016/j.biopha.2023.114962
7. Huang HS, Lawal B, Chiang IT, Weng YS, Kuo YC, Liu YC, Hsu FT (2023): A Novel Isotope-labeled Small Molecule Probe CC12 for Anti-glioma via Suppressing LYN-mediated Progression and Activating Apoptosis Pathways. International Journal of Biological Sciences 19(10):3209-3225. doi: 10.7150/ijbs.82266.
8. Hsu LC, Ku HJ, Lin KH, Lee KC, Hsu FT (2023): Amentoflavone Induces Caspase-dependent/-independent Apoptosis and Dysregulate Cyclin-dependent Kinase Mediated Cell Cycle in Colorectal Cancer in vitro and in vivo. Environmental Toxicology 38(5):1078-1089. doi: 10.1002/tox.23749
9. \Weng YS, Chiang IT, Tsai JJ, Liu YC, Hsu FT (2023): Lenvatinib synergistically promotes radiotherapy on hepatocellular carcinoma via inhibiting Src/STAT3/NF-kappaB mediated epithelial-mesenchymal transition and metastasis. International Journal of Radiation Oncology, Biology, Physics S0360-3016(22)03352-1. doi: 10.1016/j.ijrobp.2022.09.060.
10. Chin YC, Yang LX, Hsu FT*, Hsu CW, Chang TW, Chen HY, Chen YC, Chia C, Hung CC*, Lao MY* (2022): Iron chlorophyll-guided Fe3O4 nano-assembly and adoption of an advanced ferroptosis strategy to enhance photodynamic immunotherapy on bladder cancer. Journal of Nanobiotechnology. 11;20(1):373. doi: 10.1186/s12951-022-01575-7.
11. Chiang IT, Liu YC, Liu HS, Ahmed Ali AA, Chou SY, Hsu TI, Hsu FT (2022): Regorafenib Reverses Temozolomide-induced CXCL12/CXCR4 Signaling and Triggers Apoptosis Mechanism in Glioblastoma. Neurotherapeutics 19(2):616-634. doi: 10.1007/s13311-022-01194-y.
12. Hsu FT*, Tsai CL*, Chiang IT*, Lan KH, Yueh PF, Liang WY, Lin CS, Chao Y, Lan KL (2022): The Synergistic Effect of Abraxane that Combines Human IL15 Fused with an Albumin-binding Domain on Murine Models of Pancreatic Ductal Adenocarcinoma. Journal of Cellular and Molecular Medicine 26(7):1955-1968. doi: 10.1111/jcmm.17220.
13. Chiang IT, Lee YH, Tan ZL, Hsu FT*, Tu HF* (2022): Regorafenib Enhances Antitumor Immune Efficacy of Anti-PD-L1 Immunotherapy on Oral Squamous Cell Carcinoma. Biomedicine & Pharmacotherapy 147:112661. doi: 10.1016/j.biopha.2022.112661
14. Wu CH*, Hsu FT*, Chao TL*, Lee YH, Kuo YC (2021): Revealing the Suppression Role of Protein Kinase C delta and the p38 Mitogen-activated Protein Kinase (MAPK)/NF-κB Axis Associated with Lenvatinib-inhibited Progression of Hepatocellular Carcinoma In Vitro and In Vivo. Biomedicine & Pharmacotherapy 145:112437
15. Hsu FT, Chiang IT, Wang WS (2020): Induction of Apoptosis Through Extrinsic/Intrinsic Pathways and Suppression of ERK/NF-B Signaling Participate in the Imipramine-inhibited Progression of Glioblastoma. Journal of Cellular and Molecular Medicine 24(7):3982–4000.

- 衛生福利部醫事放射師證書

- 年度電腦斷層掃描品質保證（CT QA）證書

- 年度透視品質保證證書 (FL QA)

- 乳房X光攝影月品質保證證書（MA QA）

- 美國世界分子影像學會會員(Member of World Molecular Imaging Society, USA)。

- 美國北美放射學會會員(Member of Radiological Society of North America, USA)。

陽明交通大共同指導博士生：陳映慈、廖彩嵐

中國醫藥大學共同指導博士生：陳柏勳

中國醫藥大學共同指導碩士生：陳佩綺、董岱澄、王得禎